RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
Methods of isolating highly sialylated recombinant vitamin K dependent proteins, particularly Factor IX, by chromatographic methods are described. The highly sialylated recombinant proteins are characterized. The improved Factor IX has at least 62% N-glycosylation with 3 or 4 sialic acid residues and improved bioavailability and pharmokinetic properties.
1 . A method of isolating highly sialylated Factor IX for treatment of hemophilia comprising;
providing a preparation of Factor IX; and
separating highly sialylated foams of Factor IX.
2 . The method of claim 1 , wherein the separation is carried out by chromatography.
3 . The method of claim 2 , wherein the chromatography is carried out in the presence of calcium.
4 . The method of claim 1 , wherein the Factor IX is fully gamma-carboxylated.
5 . The method of claim 1 , further comprising:
collecting fractions enriched in highly sialylated Factor IX; and
pooling the fractions to obtain a preparation having at least 50% N-glycans with 3 or more sialic acid residues.
6 . The method of claim 1 , wherein Factor IX is recombinant.
7 . A recombinant vitamin K dependent (VKD) protein having pharmacokinetic properties that are comparable to or better than the pharmacokinetic properties of the corresponding vitamin K dependent protein derived from normal human plasma.
8 . The recombinant VKD protein of claim 7 wherein the VKD protein comprises N-linked oligosaccharides which are highly sialylated.
9 . The recombinant VKD protein of claim 8 wherein the percentage of N-linked oligosaccharides with 3 or more sialic acid residues per molecule is at least 62%.
10 . The recombinant vitamin K dependent (VKD) protein of claim 7 , wherein the VKD protein is selected from the group consisting of Factor VII, Factor IX, Factor X, Prothrombin and Protein C and structural variants of each having pharmacokinetic properties that are comparable to or better than the pharmacokinetic properties of the corresponding vitamin K dependent protein present in normal human plasma.
11 . The recombinant VKD protein of claim 7 having >100% of the initial plasma recovery after intravenous infusion relative to the corresponding VKD protein derived from normal human plasma.
12 . The recombinant VKD protein of claim 7 having >80% of the initial plasma recovery after intravenous infusion relative to the corresponding VKD protein derived from normal human plasma.
13 . The recombinant VKD protein of claim 7 having >100% of the bioavailability (AUC) after intravenous infusion relative to the corresponding VKD protein derived from normal human plasma.
14 . The recombinant VKD protein of claim 7 having >80% of the bioavailability (AUC) after intravenous infusion relative to the corresponding VKD protein derived from normal human plasma.
15 . A method of improving the bioavailability of recombinant VKD proteins when administered to a patient in need thereof which comprises increasing the glycosylation of the recombinant VKD.
16 . A preparation comprising a recombinant VKD protein which is free from contamination with plasma proteins other than the VKD protein, wherein the preparation has pharmacokinetic properties that are comparable to or better than the pharmacokinetic properties of the corresponding VKD protein derived from normal human plasma.
17 . The preparation of claim 16 , wherein the VKD protein comprises N-linked oligosaccharides which are highly sialylated.
18 . The preparation of claim 17 , wherein the percentage of N-linked oligosaccharides with 3 or more sialic acid residues per molecule is at least 62%.
19 . The preparation of claim 16 , wherein the recombinant vitamin K dependent (VKD) blood coagulation protein is selected from the group consisting of Factor VII, Factor IX, Factor X, Prothrombin and Protein C and structural variants of each having pharmacokinetic properties that are comparable to or better than the pharmacokinetic properties of the corresponding vitamin K dependent protein present in normal human plasma.